Diakron Pharmaceuticals

    The Company’s lead compound, DP-4088, a small molecule, is an oral direct thrombin inhibitor in late Phase I that has completed proof of concept in man. DP-4088 is a once a day drug. The DP-4088 target market is projected to be $5.0 billion in 2014. DP-4088 can capture a significant portion of this market.
The Company’s T-type Calcium Channel Blocker (TCCB) DP-3005 is in pre-clinical phase. There are no T-type CCB’s marketed worldwide. TCCBs have been shown to be effective in hypertension and angina. The market for hypertension is currently approximately $40 billion annually worldwide ($20 billion in the US). 
The company has a diabetes program in the research phase.